OXB completes acquisition of remaining stake in
US subsidiary
Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market
Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has acquired the remaining 10% stake in its US subsidiary from Q32 Bio, Inc. (Q32), bringing its ownership, as planned, to 100%.
As previously disclosed in the Company’s Preliminary Results on 9 April 2025, OXB US Inc., OXB’s wholly owned US subsidiary, exercised its call option on 1 March 2025 to acquire the final 10% interest in OXB US LLC from Q32. The stake was originally held by Homology Medicines, Inc (Homology), which merged with Q32 in 2024. The transfer of Q32’s 10% holding to OXB US Inc., means that OXB US LLC is now wholly owned by OXB.
OXB US LLC was originally established in Bedford, MA, in 2022, as an AAV manufacturing and innovation business. The facility has since been fully integrated into OXB’s global network, successfully completing the tech transfer of its lentiviral platform to the site in 2024. Spanning 96,000 ft², the site offers lentiviral and AAV vector capabilities and has supported the onboarding of multiple new programmes in the US, as part of OXB’s global cell and gene therapy development and manufacturing network.
Dr Frank Mathias, Chief Executive Officer of OXB, commented: “The progression to full ownership of our US business marks an important step for OXB. It strengthens our position in a key market and helps meet growing demand for high-quality vector manufacturing – a critical enabler of the expanding cell and gene therapy market.
“Our presence in the US, alongside our existing sites in the UK and France, gives clients access to deep expertise across AAV and lentiviral-based therapies. Through OXB’s network, we are able to support clients globally across all key vector types – from early-stage development through to commercialisation.”
-Ends-
Enquiries:
OXB:
Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
- Wolters Kluwer successfully prices €500 million five-year Eurobond - June 23, 2025
- Gray Stations and InvestigateTV Honored by IRE Awards for Outstanding Investigative Journalism - June 23, 2025
- Goddard Systems, LLC, Welcomes Tim Linderman as Senior Vice President and Chief Growth Officer - June 23, 2025
